bb2121
Author: Dominique Fontanilla
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Pipeline product bb2121 (Celgene/bluebird bio) is a second-generation chimeric antigen receptor T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA), a promising target for immunotherapy which is found in 60–70% of multiple myeloma (MM) patients. CAR-T therapy involves the extraction of autologous T cells, which are then genetically engineered to express CAR and reintroduced back into the patient, where the cells are expected to target cancer cells.
The drug is in Phase II development for fourth-line MM and has the potential to be the first CAR-T therapy approved for this indication. As well as representing a possible new drug class for MM, this breakthrough therapy has shown very high efficacy in a patient population that has few treatment options. Phase I trial data in heavily pre-treated patients (ClinicalTrials.gov identifier: NCT02658929) showed that bb2121 results in deep and durable responses, with an overall response rate of 95.5% and complete response rate of 50%. Although bb2121’s initial target patient population will be limited to later lines of therapy, Celgene plans to develop the bb2121 program in earlier lines of therapy, which will increase its market potential.
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 bb2121 : Multiple myeloma
LIST OF FIGURES
11 Figure 1: bb2121 for multiple myeloma – SWOT analysis
12 Figure 2: Datamonitor Healthcare’s drug assessment summary for bb2121 in multiple myeloma
13 Figure 3: Datamonitor Healthcare’s drug assessment summary for bb2121 in multiple myeloma
15 Figure 4: bb2121 sales for multiple myeloma across the US and five major EU markets, by country, 2017–26
LIST OF TABLES
6 Table 1: bb2121 drug profile
8 Table 2: bb2121 Phase II trial in multiple myeloma
10 Table 3: bb2121 early-phase data in multiple myeloma
16 Table 4: bb2121 sales for multiple myeloma across the US and five major EU markets, by country ($m), 2017–26
18 Table 5: Patients treated with bb2121 across the US and five major EU markets, by country, 2017–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Isatuximab 
Sign up to the